Evidence map›Paper›PMID 25276325›Full record

ArticleRare tumors2014

History of the rare cancer network and past research.

René-Olivier Mirimanoff, Mahmut Ozsahin, Juliette Thariat, Enis Ozyar, Ulrike Schick, Berrin Pehlivan, Marco Krengli, Alessandra Franzetti Pellanda, Hansjörg Vees, Ling Cai and 6 more

Abstract readCase Reports
In one paragraph

Article in Rare tumors, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

René-Olivier MirimanoffDepartment of Radiation Oncology, University of Lausanne Medical Center , Lausanne, Switzerland.
Mahmut OzsahinDepartment of Radiation Oncology, University of Lausanne Medical Center , Lausanne, Switzerland.
Juliette ThariatDepartment of Radiation Oncology, Centre Lacassagne , Nice, France.
Enis OzyarDepartment of Radiation Oncology, Acibadem University , Istanbul, Turkey.
Ulrike SchickDepartment of Radiation Oncology, University Hospital , Geneva, Switzerland.
Berrin PehlivanDepartment of Radiation Oncology, Medstar Antalya Hospital , Antalya, Turkey.
Marco KrengliDivision of Radiotherapy, University of Piemonte Orientale , Novara, Italy.
Alessandra Franzetti PellandaRadiotherapy Service, Clinica Luganese SA no profit , Lugano, Switzerland.
Hansjörg VeesDepartment of Radiation Oncology, University Hospital , Geneva, Switzerland.
Ling CaiDepartment of Radiation Oncology, Sun Yat-Sen University Cancer Center , Guangzhou, China.
Luciano ScandolaroDepartment of Radiotherapy, Ospedale S. Anna , Como, Italy.
Yazid BelkacemiDepartment of Radiation Therapy and Breast Center, Henri Mondor University Hospital, Université Paris Est Créteil (UPEC) , Créteil, France.
Salvador VillàRadiation Oncology, Institut Català d'Oncologia , Badalona, Barcelona, Catalonia, Spain.
Sefik IgdemDepartment of Radiation Oncology, Istanbul Bilim University , Istanbul, Turkey.
Myroslav LutsykDepartment of Radiation Oncology, Ram Bam Medical Center , Haifa, Israel.
Robert C MillerDepartment of Radiation Oncology, Mayo Clinic , Rochester, MN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately, twenty years ago, the Rare Cancer Network (RCN) was formed in Lausanne, Switzerland, to support the study of rare malignancies. The RCN has grown over the years and now includes 130 investigators from twenty-four nations on six continents. The network held its first international symposium in Nice, France, on March 21-22, 2014. The proceedings of that meeting are presented in two companion papers. This manuscript reviews the history of the growth of the RCN and contains the abstracts of fourteen oral presentations made at the meeting of prior RCN studies. From 1993 to 2014, 74 RCN studies have been initiated, of which 54 were completed, 10 are in progress or under analysis, and 9 were stopped due to poor accrual. Forty-four peer reviewed publications have been written on behalf of the RCN.

Indexed as

cancercarcinomadiseasesrareRare Cancer Network

Identifiers

PMID25276325
PMCPMC4178278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.